Company profile: Neos Therapeutics
1.1 - Company Overview
Company description
- Provider of oral drug delivery solutions developing controlled time-release technologies, offering CNS stimulants for ADHD (ADZENYS XR-ODT; COTEMPLA XR-ODT), Karbinal ER for allergic conditions, prescription fluoride supplements (Poly-Vi-Flor, Tri-Vi-Flor), the RxConnect patient access program, and AR101 (enzastaurin), a therapeutic candidate for vascular Ehlers-Danlos Syndrome (VEDS).
Products and services
- COTEMPLA XR-ODT: Central nervous system stimulant for ADHD treatment in patients aged 6 to 17 years, utilizing an XR-ODT formulation
- ADZENYS XR-ODT: Central nervous system stimulant for treating ADHD in patients aged 6 years and older, delivered in an XR-ODT formulation
- Karbinal ER: Indicated for treating allergic conditions such as seasonal and perennial allergic rhinitis, using an ER formulation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Neos Therapeutics
NeuroPace
HQ: United States
Website
- Description: Provider of implantable neurostimulation devices for neurological disorders, featuring the FDA-approved RNS System for epilepsy to monitor brain activity, detect unusual patterns, and deliver responsive pulses to prevent seizures. Offers personalized neuromodulation based on patient brain activity, the nSight platform for remote data access, and clinical studies (NAUTILUS, RESPONSE, and other RNS System trials).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeuroPace company profile →
Impulse Monitoring
HQ: United States
Website
- Description: Provider of intraoperative neurophysiologic monitoring solutions to hospitals and other healthcare facilities, offering insight into the nervous system during spinal, nerve, and brain-related surgeries. Solutions include IONM delivering real-time data and alerts to help reduce surgical risk, plus EEG, ECoG, EMG, and SSEP for diagnosis and intraoperative monitoring.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Impulse Monitoring company profile →
Reviva Pharma
HQ: United States
Website
- Description: Provider of clinical-stage pharmaceutical therapies, including Brilaroxazine (RP5063), a serotonin and dopamine receptor modulator in development for neuropsychiatric conditions such as schizophrenia, bipolar disorder, major depressive disorder, Alzheimer's disease, Parkinson's disease psychosis, and ADHD, and RP1208, a triple reuptake inhibitor for depression and obesity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Reviva Pharma company profile →
Axsome Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies for neurological disorders, including Auvelity for major depressive disorder and Sunosi to improve wakefulness in adults with excessive daytime sleepiness due to obstructive sleep apnea or narcolepsy; developing AXS-05 for Alzheimer’s disease agitation and smoking cessation, AXS-07 for acute migraine, and AXS-12 for narcolepsy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Axsome Therapeutics company profile →
Newronika
HQ: Italy
Website
- Description: Provider of innovative brain neuromodulation technologies that translate deep biosignal decoding into clinical practice to improve treatments, health, and wellness. Products include AlphaDBS, a closed-loop implant that adapts stimulation based on real-time neuronal biosignal activity, and WebBioBank, a cloud database for collecting and analyzing biosignal data from the AlphaDBS implantable pulse generator.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Newronika company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Neos Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Neos Therapeutics
2.2 - Growth funds investing in similar companies to Neos Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Neos Therapeutics
4.2 - Public trading comparable groups for Neos Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →